Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify pain sources in chronic low back pain, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. Based in Beverly Hills, this private practice is recognized for expertise in complex spinal procedures and high surgical volume, reflecting growing interest in integrating Aclarion's Nociscan platform into real-world clinical workflows.
The CLARITY trial is a prospective, randomized, multi-center study evaluating Nociscan in 300 patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS Back at 12 months compared to baseline. Aclarion anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.
“I have spent more than 25 years practicing spinal surgery in Beverly Hills, and my perspective is shaped not only by that experience, but also by having undergone multiple spine surgeries myself,” said Todd Lanman, MD, Neurosurgeon and Founder of Lanman Spinal Neurosurgery. “Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs. This ability to match the right procedure to the right patient is what moves the field forward.”
Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the significance of private practice involvement: “Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice.”
Chronic low back pain affects approximately 266 million people worldwide. Aclarion's Nociscan platform is the first evidence-supported SaaS solution to noninvasively help physicians distinguish between painful and nonpainful discs using chemical biomarkers from magnetic resonance spectroscopy. When used with other diagnostic tools, Nociscan demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
For more information about CLARITY, visit CLARITY Trial. To find a Nociscan center, view the site map here.
